In The Media

In The Media Washington Post

Amylyx’s New ALS Drug Costs $158,000 and Might Not Even Work

Interview

Featured Fellow:

Holly Fernandez Lynch, JD, MBE

October 4, 2022

In The Media STAT

How Can the Latest Alzheimer’s Therapy Reach Patients? Follow This Trustworthy Process

Author

Featured Fellow:

Jason Karlawish, MD

October 3, 2022

In The Media Bloomberg Law

Huntington Ingalls’ COVID Insurance Win Gives Hope to Businesses

Interview

Featured Fellow:

Tom Baker, JD

October 3, 2022

In The Media CNN

ALS Drug Gets FDA Approval Despite Uncertainty About Effectiveness

Interview

Featured Fellow:

Holly Fernandez Lynch, JD, MBE

September 30, 2022

In The Media Philadelphia Inquirer

What We Learned From Philadelphia’s Vaccine Lottery

Author

Featured Fellow:

Katherine Milkman, PhD

September 29, 2022

In The Media NBC News

FDA Approves Controversial New Drug Designed to Slow the Progress of ALS

Interview

Featured Fellow:

Holly Fernandez Lynch, JD, MBE

September 29, 2022

In The Media STAT

How Health Systems Can Truly Value Black Lives: Help Close the Racial Wealth Gap

Authors

Featured Fellows:

September 29, 2022

In The Media Philadelphia Inquirer

$50 Million Gift to Penn Is Aimed at New Treatments for Autoimmune Disease

Interview

Featured Fellow:

David Fajgenbaum, MD, MSc

September 28, 2022

In The Media Philadelphia Inquirer

Penn Medicine Teams With Independence Blue Cross on Primary Care Venture

Interview

Featured Fellow:

Kevin B. Mahoney, MBA

September 27, 2022

In The Media The Guardian

Biden’s Claim That COVID Pandemic Is Over Sparks Debate Over Future

Interview

Featured Fellow:

Ezekiel J. Emanuel, MD, PhD

September 24, 2022

In The Media Forbes

University of Pennsylvania Receives $55 Million Gift To Study, Treat Hereditary Cancers

Interview

Featured Fellow:

Susan M. Domchek, MD

September 21, 2022

In The Media NPR

FDA Seems Poised To Approve a New Drug for ALS, but Does It Work?

Interview

Featured Fellow:

Holly Fernandez Lynch, JD, MBE

September 21, 2022

Amylyx’s New ALS Drug Costs $158,000 and Might Not Even Work

How Can the Latest Alzheimer’s Therapy Reach Patients? Follow This Trustworthy Process

Huntington Ingalls’ COVID Insurance Win Gives Hope to Businesses

ALS Drug Gets FDA Approval Despite Uncertainty About Effectiveness

What We Learned From Philadelphia’s Vaccine Lottery

FDA Approves Controversial New Drug Designed to Slow the Progress of ALS

How Health Systems Can Truly Value Black Lives: Help Close the Racial Wealth Gap

$50 Million Gift to Penn Is Aimed at New Treatments for Autoimmune Disease

Penn Medicine Teams With Independence Blue Cross on Primary Care Venture

Biden’s Claim That COVID Pandemic Is Over Sparks Debate Over Future

University of Pennsylvania Receives $55 Million Gift To Study, Treat Hereditary Cancers

FDA Seems Poised To Approve a New Drug for ALS, but Does It Work?

Search